This phase III study is evaluating whether receiving targeted therapy (imatinib) for three or five years is more effective in people with gastrointestinal stromal tumours following surgery.
This trial is treating patients with gastrointestinal stromal tumours.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study
Commercial Sponsor
Heikki Joensuu
Summary
This study is recruiting people who have verified gastrointestinal stromal tumour (GIST) with a high risk of recurrence, despite removal of all macroscopic GIST tissue during surgery and having received 3 years of adjuvant imatinib. Study participants will be randomly allocated to either Arm A or Arm B. In Arm A (Experimental), participants will continue receiving imatinib (400mg/day for 24 months). In Arm B, participants will stop receiving imatinib. All participants will be followed up using blood tests and scans of the abdomen.
Recruiting Hospitals Read More